Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making more emergency adrenaline auto-injectors available in community settings.

In November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicine’s Adrenaline Auto-injector Expert Working Group, with wide-ranging input from patient groups, leading allergy experts, and healthcare professionals, published a report which outlined recommendations for the safe and effective use of adrenaline auto-injectors (AAIs), including quicker treatment, to help save lives. The MHRA has worked alongside the Department and the wider health system to take forward these recommendations, some of which are already in place.

In June 2023, the MHRA, with the support of allergy awareness advocates, launched a safety campaign to raise awareness of anaphylaxis and to provide advice on the use of AAIs. The MHRA produced a toolkit of resources for health and social care professionals to support the safe and effective use of AAIs. Alongside this, the MHRA produced guidance, which states that prescribers should prescribe two AAIs to make sure patients always have the second dose, and that those who are prescribed AAIs should always carry two AAIs at all times.

The majority of community pharmacies offer vaccinations. As part of offering this service, pharmacy contractors are expected to recognise and treat anaphylaxis. They must have immediate access to an anaphylaxis pack, including adrenaline. They are required to undertake training to administer adrenaline from an ampoule using a needle and AAIs in case of anaphylactic reactions.